Overview

A Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in the Treatment of Behçet Disease

Status:
Completed
Trial end date:
2012-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess whether Apremilast is safe and effective in the treatment of patients with Behcet Disease.
Phase:
Phase 2
Details
Lead Sponsor:
Amgen
Celgene Corporation
Treatments:
Apremilast
Thalidomide